A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

A Randomized Phase 2, Double Blind, Placebo-Controlled, Multi-Center Crossover Study Of PF-03654746 As A Daily Treatment For Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy

Histaminergic agents are known to be involved with the sleep/wake cycle. This compound is a histaminergic agent which therefore may improve alertness and awakeness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy. Significant improvement in EDS when treated with this compound compared to placebo in patients with narcolepsy is hypothesized.

Inclusion Criteria:

• ISDC diagnosis of narcolepsy
• Excessive Daytime Sleepiness in association with a diagnosis of narcolepsy
• An MWT (Maintenance of Wakefulness Test) average sleep latency of under 15 minutes at Baseline

Exclusion Criteria:

• No other diagnosed sleep disorders (e.g., sleep apnea)
• Major medical disorders
• Major psychiatric disorders